<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01536535</url>
  </required_header>
  <id_info>
    <org_study_id>U01DK095745-01</org_study_id>
    <secondary_id>1U34DK090804</secondary_id>
    <nct_id>NCT01536535</nct_id>
  </id_info>
  <brief_title>Predicting Response to Standardized Pediatric Colitis Therapy</brief_title>
  <acronym>PROTECT</acronym>
  <official_title>Multicenter Open-label Study Evaluating the Safety and Efficacy of Standardized Initial Therapy Using Either Mesalamine or Corticosteroids Then Mesalamine to Treat Children and Adolescents With Newly Diagnosed Ulcerative Colitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Connecticut Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Connecticut Children's Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label study to determine the safety and effectiveness (how well
      it works) of two standardized treatments called &quot;mesalamine&quot; (Pentasa®) and &quot;prednisone&quot; in
      children with newly diagnosed Ulcerative Colitis (UC). Standardized treatments are types of
      treatments agreed upon and used by many qualified doctors. The medications being used in this
      study are considered &quot;standard of care&quot;. Currently the ways in which these medicines are used
      (doses, frequency of dosing) may vary from site to site. This study will determine response
      to a standardized way of giving these medicines.

      This study will also identify biomarkers for ulcerative colitis. Biomarkers are things that
      doctors can find in blood, stool, or bowel tissue that indicate how much inflammation there
      is in the bowel, how the inflammation is produced, and whether the inflammation is responding
      to treatment. Collecting response and remission (free of symptoms) information on these
      standardized treatments and the &quot;biomarkers&quot; can possibly help doctors create a model, or
      plan to know which children with UC may respond quickly, or which children may develop
      complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ulcerative Colitis (UC) denotes a phenotype of chronic inflammatory bowel disease (IBD),
      where inflammation is localized to the colonic mucosa, and extends from the rectum proximally
      in varying extents. The disorder is thought to result from an inappropriate activation of the
      mucosal immune system by antigens derived from both the host epithelium and the enteric
      flora, in genetically susceptible individuals. UC is strikingly heterogeneous with respect to
      age of onset, anatomical extent and disease course, with some experiencing chronically active
      severe disease, while others have intermittent periods of clinical remission and disease
      exacerbation. Patients' therapeutic responses vary. The reasons underlying such variability
      are not well understood. Although it has been widely hypothesized that several genes may
      influence the development of UC, and modify its phenotypic expression and severity, to date
      there are few confirmed examples of such relationships.

      It has been postulated that the 5-aminosalicylate drugs exert their anti-inflammatory effect
      locally at the intestinal mucosa. Mechanisms likely include inhibition of 5-lipoxygenase
      resulting in decreased production of leukotriene B4, scavenging of reactive oxygen
      metabolites, prevention of up-regulation of leukocyte adhesion molecules, and inhibition of
      Interleukin 1 (IL-1) synthesis. Though multiple studies have shown the efficacy of
      aminosalicylates in inducing and maintaining remission in adults with UC, there are few data
      in children.

      Corticosteroids (CS) have been the mainstay of treatment of severe UC since efficacy was
      first demonstrated in the 1955 randomized controlled trial by Truelove and Witts. Recent
      practice guidelines developed in adults support their use because of rapid onset of action
      and significant efficacy though CS dependency is noted. Though no controlled data on their
      use have been reported in children they are frequently used in this population. A recent
      report from investigators leading the prospective Pediatric IBD Collaborative Research Group
      Registry described 97 subjects with a diagnosis of UC and a minimum of 1 year follow-up; 79%
      received CS. At diagnosis 81% of CS treated patients had moderate/severe disease, and 81% had
      pancolitis. Clinically inactive disease, determined by physician global assessment, was noted
      in 60% at 3 months following CS therapy, but by one year 45% were considered CS dependent
      despite the frequent use of immunomodulators (IM). Among those children with initially
      moderate to severe disease in clinical remission at 3 months, about two-thirds had stopped
      the CS by one year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 10, 2012</start_date>
  <completion_date type="Actual">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Corticosteroid Free Remission (SFR)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Week 52 CS-free remission: Number of participants with a PUCAI &lt; 10 and no corticosteroids (CS) for 28 days without additional therapy or colectomy. Participants in both groups received corticosteroids, biologics, or colectomies, if symptomatic.
The Pediatric Ulcerative Colitis Activity Index (PUCAI) is a non-invasive disease activity index. The index measures include abdominal pain, rectal bleeding, stool consistency, number of stools per 24 hours, nocturnal stools, and activity level. A total score less than 10 indicates remission, Mild disease activity is 10-30, Moderate 35-60, Severe disease activity 65-85.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Needed Additional Therapy or Colectomy</measure>
    <time_frame>Within 52 weeks</time_frame>
    <description>Number of participants who needed additional therapy or colectomy. Additional therapy included Anti-Tumour Necrosis Factor alpha (TNFα), Calcineurin inhibitor, Immunomodulator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Receiving a Colectomy</measure>
    <time_frame>Within 52 weeks</time_frame>
    <description>Number of participants who received a colectomy within 52 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">431</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Mild UC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild = Initiated on mesalazine, or on oral CS with Pediatric Ulcerative Colitis Activity Index (PUCAI) &lt; 45
Patients can be treated with any of the therapies noted below:
Mesalazine: doses is rounded to the nearest 500mg increment, maximum dose of 75 mg/kg/day Oral corticosteroids:1-1.5 mg/kg/day, rounded up to the nearest 5 mg value
IV corticosteroids:
Additional Therapies:
Calcineurin inhibitor (cyclosporine, tacrolimus) or anti-Tumour Necrosis Factor alpha (TNFα) therapy: These therapies may also be instituted if in the judgment of the attending physician is needed.
Immunomodulator or biologic therapy: thiopurine then dosing of azathioprine:2.5-3 mg/kg/day; 6-MP at 1-1.5 mg/kg/day Colectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate to Severe UC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate/Severe = Initiated on IV CS, or oral CS with PUCAI ≥45
Patients can be treated with any of the therapies noted below:
Mesalazine: doses is rounded to the nearest 500mg increment, maximum dose of 75 mg/kg/day Oral corticosteroids:1-1.5 mg/kg/day, rounded up to the nearest 5 mg value
IV corticosteroids:
Additional Therapies:
Calcineurin inhibitor (cyclosporine, tacrolimus) or anti-TNFα therapy: These therapies may also be instituted if in the judgment of the attending physician is needed.
Immunomodulator or biologic therapy: thiopurine then dosing of azathioprine:2.5-3 mg/kg/day; 6-Mercaptopurine (MP) at 1-1.5 mg/kg/day Colectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalazine</intervention_name>
    <description>Mesalazine (Pentasa) comes in 500mg capsules, and doses will need to be rounded to the nearest 500mg increment, with a maximum dose of 76 mg/kg/day. The average dose for the pediatric population will be approximately 70 mg/kg/day. Patients will be allowed to escalate to the final dose over 4 days to minimize side-effects such as headache.</description>
    <arm_group_label>Mild UC</arm_group_label>
    <arm_group_label>Moderate to Severe UC</arm_group_label>
    <other_name>Pentasa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Corticosteroid</intervention_name>
    <description>Treatment with IV Corticosteroid</description>
    <arm_group_label>Mild UC</arm_group_label>
    <arm_group_label>Moderate to Severe UC</arm_group_label>
    <other_name>Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Corticosteroids</intervention_name>
    <description>Treatment with oral corticosteroids</description>
    <arm_group_label>Mild UC</arm_group_label>
    <arm_group_label>Moderate to Severe UC</arm_group_label>
    <other_name>Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Additional Therapies</intervention_name>
    <description>Anti-TNFα, Calcineurin inhibitor, Immunomodulator</description>
    <arm_group_label>Mild UC</arm_group_label>
    <arm_group_label>Moderate to Severe UC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colectomy</intervention_name>
    <description>Colectomy</description>
    <arm_group_label>Mild UC</arm_group_label>
    <arm_group_label>Moderate to Severe UC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 4years and ≤17 years at initiation of therapy (achieved 4th birthday, not yet
             18th)

          -  Weight ≥15 kg

          -  New diagnosis of ulcerative colitis established by standard clinical, endoscopic, and
             histologic features at the PROTECT study site

          -  Colitis extending beyond the rectosigmoid (Paris classification E2, E3, or E4)[144].
             If a patient is seriously ill and the clinician does not advance the colonoscope
             beyond the sigmoid colon but the clinical condition of the patient highly suggests
             more extensive disease then that patient is eligible for study.

          -  Disease activity by PUCAI of ≥10 at diagnosis

          -  No therapy previously initiated to treat the newly diagnosed ulcerative colitis

          -  Stool culture negative for routine enteric pathogens (Salmonella, Shigella,
             Campylobacter, E. coli 0157:H7) and Clostridium difficile toxin. Recent successful
             treatment for Clostridium difficile does not exclude a patient if toxin now absent.
             However, the patient must be a minimum of 5 weeks from the time treatment was started
             at the time toxin is absent.

          -  Stool study negative for enteric parasites (ova and parasites)

          -  Parent/guardian consent and patient assent

          -  Ability to remain in follow-up for a minimum of one year from diagnosis

          -  Female patients of child bearing age must have a negative urine pregnancy test and
             practice acceptable contraception (e.g., abstinence, intramuscular or hormonal
             contraception, two barrier methods (e.g., condom, diaphragm, or spermicide),
             intrauterine device, verbal report of the partner with history of vasectomy, or be
             surgically sterile). All female patients of childbearing potential (post-menarche)
             will undergo urine pregnancy testing at screening and must not be lactating.

        Exclusion Criteria:

          -  Clinical, endoscopic, radiologic, or histologic evidence suggesting Crohn's disease
             (CD) consistent with Paris and North American Society for Pediatric Gastroenterology,
             Hepatology and Nutrition (NASPGHAN) criteria [144, 145]

          -  A previous diagnosis of inflammatory bowel disease for which treatment was given

          -  Evidence of any active enteric infection at the time of study entry

          -  Use of any oral CS for non-gastrointestinal indication within the past 4 weeks (e.g.,
             asthma). Use of inhaled CS does not exclude a patient.

          -  History of use of IM or anti-TNFα agent for other medical conditions (e.g., juvenile
             rheumatoid arthritis) within the past 6 months

          -  Use of Accutane within the past 4 weeks

          -  Use of any investigational drug within the past four weeks

          -  Use of any 5-aminosalicylate within the past 4 weeks

          -  Pregnancy

          -  Subjects with poorly controlled medical conditions (e.g. diabetes, congestive heart
             failure)

          -  Proctitis or proctosigmoiditis only (Paris classification E1) on colonoscopic
             evaluation

          -  Chronic renal disease (BUN and serum creatinine &gt;1.5 times the upper normal limit)

          -  Hepatic disease (AST or Alkaline phosphatase (ALP) greater than 3 times the upper
             normal limit in the absence of concomitant liver disease associated with IBD following
             full evaluation)

          -  History of allergy or hypersensitivity to salicylates, aminosalicylates, or any
             component of the Pentasa capsule.

          -  History of coexisting chronic illness or evidence of significant organic or
             psychiatric disease on medical history or physical examination, which, in the
             Investigator's opinion, would prevent participation in the study

          -  History or presence of any condition causing malabsorption or an effect on
             gastrointestinal (GI) motility, or history of extensive small bowel resection (greater
             than half the length of the small intestine).

          -  The finding of Helicobacter pylori at the time of evaluation does not exclude the
             patient from the study. Whether to treat this patient for Helicobacter pylori and when
             will be left to the discretion of the site.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Hyams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Connecticut Children's Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lee Denson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sonia Davis, DrPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Collaborative Studies Coordinating Center - UNC-CH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Children's Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Children's Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins Children's Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goryeb Children's Hospital / Atlantic Health</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Children's Hospital of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cohen Children's Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morgan Stanley Children's Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golisano Children's Hospital SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel HIll</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hasbro Children's Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monroe Carell Jr. Children's Hospital at Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center (University of Utah)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3k6r8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.protectstudy.org</url>
    <description>PROTECT Study Homepage</description>
  </link>
  <results_reference>
    <citation>Hyams JS, Davis S, Mack DR, Boyle B, Griffiths AM, LeLeiko NS, Sauer CG, Keljo DJ, Markowitz J, Baker SS, Rosh J, Baldassano RN, Patel A, Pfefferkorn M, Otley A, Heyman M, Noe J, Oliva-Hemker M, Rufo P, Strople J, Ziring D, Guthery SL, Sudel B, Benkov K, Wali P, Moulton D, Evans J, Kappelman MD, Marquis A, Sylvester FA, Collins MH, Venkateswaran S, Dubinsky M, Tangpricha V, Spada KL, Britt A, Saul B, Gotman N, Wang J, Serrano J, Kugathasan S, Walters T, Denson LA. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study. Lancet Gastroenterol Hepatol. 2017 Dec;2(12):855-868. doi: 10.1016/S2468-1253(17)30252-2. Epub 2017 Sep 20.</citation>
    <PMID>28939374</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 16, 2012</study_first_submitted>
  <study_first_submitted_qc>February 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2012</study_first_posted>
  <results_first_submitted>August 6, 2019</results_first_submitted>
  <results_first_submitted_qc>August 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2019</results_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>mesalamine</keyword>
  <keyword>corticosteroids</keyword>
  <keyword>PROTECT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared 6 months after the primary publication of the manuscript appears on line.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be shared 6 months after the primary publication of the manuscript appears on line.</ipd_time_frame>
    <ipd_access_criteria>NIH repository list serve to be determined</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 2, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT01536535/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment and enrollment began in July 2012 and ended in April 2015. Final study visits were in April 2016 at which time all study patients had a minimum of one year follow up. Patients were recruited from 29 centers in the United States and Canada.</recruitment_details>
      <pre_assignment_details>Participants were consented at diagnostic colonoscopy obtaining biological specimens (DNA, serum, rectal tissue, stool for microbiome). After diagnosis of Ulcerative Colitis, they began treatment dictated by initial disease severity and provider/patient choice. Three patients were untreated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mild UC Disease</title>
          <description>Mild = Initiated on mesalazine, or on oral CS with Pediatric Ulcerative Colitis Activity Index (PUCAI) &lt; 45</description>
        </group>
        <group group_id="P2">
          <title>Moderate to Severe UC</title>
          <description>Moderate/Severe = Initiated on IV CS, or oral CS with PUCAI ≥45</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="178"/>
                <participants group_id="P2" count="250"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="163">Patients either completed week 52 visit or had early colectomy or had additional therapy.</participants>
                <participants group_id="P2" count="237">Patients either completed week 52 visit or had early colectomy or had additional therapy.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mild UC</title>
          <description>Mild = Initiated on mesalamine, or on oral CS with PUCAI &lt; 45</description>
        </group>
        <group group_id="B2">
          <title>Moderate to Severe UC</title>
          <description>Moderate/Severe = Initiated on IV CS, or oral CS with PUCAI ≥45</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="178"/>
            <count group_id="B2" value="250"/>
            <count group_id="B3" value="428"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="178"/>
                    <count group_id="B2" value="250"/>
                    <count group_id="B3" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.6" spread="3.4"/>
                    <measurement group_id="B2" value="12.7" spread="3.2"/>
                    <measurement group_id="B3" value="12.7" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="178"/>
                    <count group_id="B2" value="250"/>
                    <count group_id="B3" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="212"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Corticosteroid Free Remission (SFR)</title>
        <description>Week 52 CS-free remission: Number of participants with a PUCAI &lt; 10 and no corticosteroids (CS) for 28 days without additional therapy or colectomy. Participants in both groups received corticosteroids, biologics, or colectomies, if symptomatic.
The Pediatric Ulcerative Colitis Activity Index (PUCAI) is a non-invasive disease activity index. The index measures include abdominal pain, rectal bleeding, stool consistency, number of stools per 24 hours, nocturnal stools, and activity level. A total score less than 10 indicates remission, Mild disease activity is 10-30, Moderate 35-60, Severe disease activity 65-85.</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild UC</title>
            <description>Mild = Initiated on mesalazine, or on oral CS with PUCAI &lt; 45</description>
          </group>
          <group group_id="O2">
            <title>Moderate to Severe UC</title>
            <description>Moderate/Severe = Initiated on IV CS, or oral CS with PUCAI ≥45</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Corticosteroid Free Remission (SFR)</title>
          <description>Week 52 CS-free remission: Number of participants with a PUCAI &lt; 10 and no corticosteroids (CS) for 28 days without additional therapy or colectomy. Participants in both groups received corticosteroids, biologics, or colectomies, if symptomatic.
The Pediatric Ulcerative Colitis Activity Index (PUCAI) is a non-invasive disease activity index. The index measures include abdominal pain, rectal bleeding, stool consistency, number of stools per 24 hours, nocturnal stools, and activity level. A total score less than 10 indicates remission, Mild disease activity is 10-30, Moderate 35-60, Severe disease activity 65-85.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Needed Additional Therapy or Colectomy</title>
        <description>Number of participants who needed additional therapy or colectomy. Additional therapy included Anti-Tumour Necrosis Factor alpha (TNFα), Calcineurin inhibitor, Immunomodulator</description>
        <time_frame>Within 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild UC Disease</title>
            <description>Mild = Initiated on mesalazine, or on oral CS with PUCAI &lt; 45</description>
          </group>
          <group group_id="O2">
            <title>Moderate to Severe UC</title>
            <description>Moderate/Severe = Initiated on IV CS, or oral CS with PUCAI ≥45</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Needed Additional Therapy or Colectomy</title>
          <description>Number of participants who needed additional therapy or colectomy. Additional therapy included Anti-Tumour Necrosis Factor alpha (TNFα), Calcineurin inhibitor, Immunomodulator</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Receiving a Colectomy</title>
        <description>Number of participants who received a colectomy within 52 weeks</description>
        <time_frame>Within 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild UC Disease</title>
            <description>Mild = Initiated on mesalazine, or on oral CS with PUCAI &lt; 45</description>
          </group>
          <group group_id="O2">
            <title>Moderate to Severe UC</title>
            <description>Moderate/Severe = Initiated on IV CS, or oral CS with PUCAI ≥45</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Receiving a Colectomy</title>
          <description>Number of participants who received a colectomy within 52 weeks</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from Baseline through to the 52 week visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mild UC</title>
          <description>Mild = Initiated on 5-Aminosalicylates (ASA) or on oral CS with PUCAI &lt; 45</description>
        </group>
        <group group_id="E2">
          <title>Moderate to Severe UC</title>
          <description>Moderate/Severe = Initiated on IV CS or oral CS with PUCAI ≥45</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalized for UC complications</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Intestinal anastomosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitus acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity to mesalamine severe headache and pleuritic chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Vasculitic rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Intentional Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="224" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Clostridium difficile</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jeffrey Hyams</name_or_title>
      <organization>Connecticut Childrens</organization>
      <phone>8605459532</phone>
      <email>jhyams@connecticutchildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

